Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099098 | 0.87 | MAPT (0.33) | HRH3ALDH1A1 | |
| SCHEMBL13098844 | 0.86 | GPR119 (0.37) | ADRA1ADGAT1GPR119 | |
| SCHEMBL13099155 | 0.86 | ADORA3 (0.41) | PDE10AADRA1AHRH3DGAT1KCNH2 | |
| SCHEMBL13099191 | 0.86 | DGAT1 (0.36) | HRH3DGAT1KCNH2ADORA2A | |
| SCHEMBL13098840 | 0.84 | GPR119 (0.38) | ADRA1AGPR119 | |
| SCHEMBL13098849 | 0.82 | PDE10A (0.36) | PDE10AADRA1AHRH3DGAT1KCNH2 | |
| SCHEMBL13098799 | 0.80 | ADORA3 (0.41) | PDE10AADRA1AHRH3DGAT1KCNH2 | |
| SCHEMBL13098816 | 0.78 | HRH3 (0.32) | HRH3 | |
| SCHEMBL13098855 | 0.76 | HRH3 (0.31) | HRH3 | |
| SCHEMBL13098863 | 0.76 | HRH3 (0.34) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | PDE10A 4039/4885ADRA1A 4341/4885HRH3 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.